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INTRODUCTION
Obeticholic acid (OCA) is a farnesoid X receptor agonist 
that serves as a novel agent for the treatment of primary 
biliary cholangitis (PBC). Its efficacy was demonstrated 
during the POISE trial where 46% of patients achieved  
the composite endpoint and 77% of patients achieved a 
reduction of alkaline phosphatase (AP) by ≥15%. We 
present a single-center real-world experience with OCA 
for PBC.
CASES
Since August 2016 our center has treated ten PBC 
patients with OCA. Patient characteristics are in Table 1. 
The mean patient age was 58.7. The median duration of 
therapy with OCA was 14.5 months. One patient did not 
use concurrent therapy with ursodiol due to cost.
The trends in AP are shown in Table 2 and Figure 1. 
Outcomes are delineated in Table 3. 
Two patients (20%) met the composite endpoint as 
delineated in the POISE trial. Seven patients (70%) had  
an improvement in AP by at least 15%. Only three of the 
patients had a dose titration from 5 mg to 10 mg. Eight 
patients had at least a mild transient rise in AP after initial 
improvement, one of which had an AP increase above 
their pre-treatment baseline.
One patient had clinically significant acute hyperlipidemia 
with a serum LDL level of 367 mg/dL. No other adverse 
events were noted including worsened pruritus.
DISCUSSION
Our real-world experience with OCA for PBC continues to 
shed new information on its treatment efficacy and safety. 
In light of recent concerns regarding the safety of OCA in 
patients with cirrhosis, our findings demonstrate that it is 
well tolerated in this population.
Despite the fact that our much of cohort did not meet the 
primary endpoint established in the POISE trial, overall 
there was a positive effect on the AP for a significant 
portion of our patients. Our data is limited by the small 
sample size and duration of therapy. Uniquely, we were 
able to show the successful use of OCA in a patient with 
chronic kidney disease.
The two patients who met the composite clinical endpoints 
did so at 2 and 6 months of therapy without titration of the 
dose to 10 mg suggesting effects are likely to be seen 
early. Interestingly, both of these patients had also had 
compensated cirrhosis.
One patient had a significant rise in AP during his therapy. 
However, this patient was not taking concomitant ursodiol 
and has significant medical comorbidities such as congestive 
heart failure that could contribute to this rise. He was 
eventually lost to follow up with questionable compliance.
Table 1. Patient Characteristics








Ursodiol? Adverse Events Other Notes
1 54 F 14 Biopsy, +AMA Yes (A) 17 Yes None None
2 67 F 11 +AMA No 16 Yes None None
3 52 M 0 Biopsy, +AMA No 25 No Severe Hyperlipidemia History of heart failure and aortic valve replacement during therapy
4 66 F 4 Biopsy, -AMA Yes (A) 20 Yes None History of CKD4, Missed one month therapy  due to medication delivery issue
5 67 F 1 Biopsy, +AMA No 24 Yes None None
6 34 F 1 Biopsy, +AMA Yes (A) 13 Yes None None
7 54 F 1 +AMA No 12 Yes None None
8 79 F 15 Biopsy, -AMA Yes (A) 8 Yes None None
9 63 F 20 Biopsy, +AMA No 9 Yes None Overlap Autoimmune Hepatitis,  Previously on OCA 2 months stopped for pruritis
10 51 F 10 Biopsy, +AMA No 11 Yes None None
Figure 1. Alkaline Phosphatase Trends During Treatment with 
Obeticholic Acid*
* T = 0 represents AP level at treatment initiation.
Table 3. Individual and Composite 
Endpoints with OCA Therapy*
*Endpoints defined by POISE clinical trial for patient outcomes at the end of 
12 months therapy.
Patient









1 Yes Yes Yes Yes
2 No No Yes No
3 No No No No
4 No No Yes No
5 Yes Yes Yes Yes
6 Yes Yes No No
7 No Yes Yes No
8 No Yes Yes No
9 No Yes Yes No
10 Yes Yes No No
Table 2. Alkaline Phosphatase Trends During Treatment with Obeticholic Acid
Pre-Treatment
Time 
(Months) Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Patient 9 Patient 10
0 209 202 875 277 272 252 350 330 259 332
1 224 215 200
2 219 564 218 175 185 311 317 206 180
3 172 300
4 213 299 188 300 254
5 657 197
Dose 10 mg 6 150 659 251 218
7 622 171 285
8 205 588
9 277
10 156 158 236




15 1311 257 93
16
17 155
18
19
20
21
22 1266
